Literature DB >> 31138589

Effective Cancer Genotyping-Many Means to One End.

Catherine B Meador1, Geoffrey R Oxnard2,3.   

Abstract

Precision cancer medicine requires effective genotyping of every patient's tumor to optimally design treatment plans. Despite its imperfect sensitivity, the rapidity and convenience of cell-free DNA sequencing makes it an essential complement to tumor genotyping, which, when used appropriately, can aid the pursuit of effective genotyping for all patients.See related article by Leighl et al., p. 4691. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2019        PMID： 31138589      PMCID： PMC6679798          DOI： 10.1158/1078-0432.CCR-19-1233

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review.

Authors:  Adrian G Sacher; Kimberly M Komatsubara; Geoffrey R Oxnard
Journal:  J Thorac Oncol       Date:  2017-06-10       Impact factor: 15.609

Review 2.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Authors:  Jason D Merker; Geoffrey R Oxnard; Carolyn Compton; Maximilian Diehn; Patricia Hurley; Alexander J Lazar; Neal Lindeman; Christina M Lockwood; Alex J Rai; Richard L Schilsky; Apostolia M Tsimberidou; Patricia Vasalos; Brooke L Billman; Thomas K Oliver; Suanna S Bruinooge; Daniel F Hayes; Nicholas C Turner
Journal:  J Clin Oncol       Date:  2018-03-05       Impact factor: 44.544

Review 3.  Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.

Authors:  Deborah B Doroshow; Miguel F Sanmamed; Katherine Hastings; Katerina Politi; David L Rimm; Lieping Chen; Ignacio Melero; Kurt A Schalper; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2019-03-01       Impact factor: 12.531

4.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

Authors:  Natasha B Leighl; Ray D Page; Victoria M Raymond; Davey B Daniel; Stephen G Divers; Karen L Reckamp; Miguel A Villalona-Calero; Daniel Dix; Justin I Odegaard; Richard B Lanman; Vassiliki A Papadimitrakopoulou
Journal:  Clin Cancer Res       Date:  2019-04-15       Impact factor: 12.531

5.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Authors:  Tony S K Mok; Yi-Long Wu; Iveta Kudaba; Dariusz M Kowalski; Byoung Chul Cho; Hande Z Turna; Gilberto Castro; Vichien Srimuninnimit; Konstantin K Laktionov; Igor Bondarenko; Kaoru Kubota; Gregory M Lubiniecki; Jin Zhang; Debra Kush; Gilberto Lopes
Journal:  Lancet       Date:  2019-04-04       Impact factor: 79.321
  5 in total
  4 in total

Review 1.  Circulating tumor DNA and liquid biopsy in oncology.

Authors:  David W Cescon; Scott V Bratman; Steven M Chan; Lillian L Siu
Journal:  Nat Cancer       Date:  2020-03-20

Review 2.  Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

3.  Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.

Authors:  Jonathan Poh; Kao Chin Ngeow; Michelle Pek; Kian-Hin Tan; Jing Shan Lim; Hao Chen; Choon Kiat Ong; Jing Quan Lim; Soon Thye Lim; Chwee Ming Lim; Boon Cher Goh; Yukti Choudhury
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.752

4.  High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content.

Authors:  Catherine B Meador; Marina S D Milan; Emmy Y Hu; Mark M Awad; Michael S Rabin; Cloud P Paweletz; Ryan Hartmaier; Gianluca Laus; Geoffrey R Oxnard
Journal:  JCO Precis Oncol       Date:  2021-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.